Digaric has a good effect on prostate cancer

Recently, at the European Urological Association meeting in Milan, Italy, researchers released a study of prostate cancer: Firmagon or degarelix can reduce the risk of cardiovascular disease compared with other prostate treatment drugs.

Bertrand Tombal from Leuven University in the French Quarter of Belgium and Kurt Miller from the Benjamin Franklin Medical Center in Berlin, Germany conducted a study that meta-analyzed 2,328 prostate cancer patients from different countries. The results showed that patients treated with degarelix reduced the risk of cardiovascular disease such as heart disease and stroke and the risk of death by more than 50% in patients with prostate cancer compared with patients receiving luteinizing hormone-releasing hormone agonists.

The study also found that the overall survival rate was significantly higher in patients treated with degarelix than in those receiving luteinizing hormone-releasing hormone agonists. The control of prostate cancer symptoms was improved, the fracture probability was reduced, and the kidneys and urinary system were poor. Less reaction.

Studies have shown that degarelix significantly reduces the risk of cardiovascular events compared to common luteinizing hormone-releasing hormone agonists that may cause a decrease in testosterone levels in men.